Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190831 | 0.80 | GPR119 (0.49) | GPR119KDM4EPKMBACE1FAAH | |
| SCHEMBL4771035 | 0.80 | GPR119 (0.47) | GPR119KDM4EPKMBACE1FAAH | |
| SCHEMBL12255478 | 0.79 | FAAH (0.50) | GPR119KDM4EPKMBACE1FAAH | |
| SCHEMBL4771557 | 0.79 | BACE1 (0.51) | GPR119KDM4EPKMBACE1FAAH | |
| SCHEMBL3865354 | 0.77 | GPR119 (0.54) | GPR119KDM4EBACE1HPGD | |
| SCHEMBL13705098 | 0.77 | GPR119 (0.40) | GPR119 | |
| SCHEMBL3155561 | 0.77 | MC4R (0.54) | GPR119HPGD | |
| SCHEMBL4773835 | 0.77 | KDM4E (0.46) | GPR119KDM4EPKMBACE1FAAH | |
| SCHEMBL4777857 | 0.77 | FAAH (0.47) | GPR119KDM4EPKMBACE1FAAH | |
| SCHEMBL2018953 | 0.77 | GPR119 (0.50) | GPR119KDM4EPKMBACE1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598407-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
| US-9598407-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-11 | — | — | US | disclosed |
| US-9012634-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2015-04-21 | — | — | US | disclosed |
| US-9012634-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2015-04-21 | — | — | US | disclosed |
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2014-06-12 | — | — | US | disclosed |
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2014-06-12 | — | — | US | disclosed |
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | FAR1, DNASE1, LAMP1 | GPR119 4284/4885KDM4E 2737/4885PKM 2704/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | GPR119 447/4885KDM4E 2791/4885PKM 4190/4885 |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | NQO2, ALPI, ECI1 | GPR119 4365/4885KDM4E 2524/4885PKM 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.